Compare AVNW & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNW | TNXP |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 198.6M |
| IPO Year | 2007 | 2008 |
| Metric | AVNW | TNXP |
|---|---|---|
| Price | $17.88 | $12.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $34.50 | N/A |
| AVG Volume (30 Days) | 247.2K | ★ 418.4K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $243,858,000.00 | $13,107,000.00 |
| Revenue This Year | $5.59 | $558.11 |
| Revenue Next Year | $7.03 | $38.29 |
| P/E Ratio | $62.17 | ★ N/A |
| Revenue Growth | 0.56 | ★ 29.85 |
| 52 Week Low | $13.92 | $11.60 |
| 52 Week High | $27.02 | $69.65 |
| Indicator | AVNW | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 44.73 |
| Support Level | $14.27 | $12.43 |
| Resistance Level | $22.45 | $15.19 |
| Average True Range (ATR) | 0.82 | 1.12 |
| MACD | 0.40 | -0.19 |
| Stochastic Oscillator | 86.35 | 16.84 |
Aviat Networks Inc provides wireless transport and access networking solutions designed to support telecommunications operators and private network providers situated in various countries. The company offers a range of microwave and millimeter wave radios, network management tools, and services that enable high-capacity, secure, and reliable data transport over wireless networks. Its products serve diverse clients including mobile operators, public safety organizations, utilities, government agencies, and enterprise customers. Aviat generates revenue from the sale of its networking equipment, professional services, and ongoing support contracts. Its operations cover various regions including the Americas, Europe, Asia Pacific, the Middle East, and Africa.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.